相关实验视频
Updated: Jul 12, 2025
05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
4.6K
迪戈辛对患有充血性心力衰竭的患者功能的潜在影响
Mesfer A Alqahtani1, Bader A Alqahtani2, Ibrahim M Dighriri3
1Department of Medical Supply, Khamis Mushayt Maternity and Children Hospital, Khamis Mushait, SAU.
Cureus
|October 19, 2023
概括
在充血性心力衰竭 (CHF) 患者中,迪戈辛治疗与估计的淋巴细胞过率 (eGFR) 的显著下降有关,这表明对功能可能有不良影响. 需要进一步的研究来证实这些发现在更大的患者队列中.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
背景情况:
- 功能障碍是充血性心力衰竭 (CHF) 患者的常见并发症.
- 迪戈辛清除与膜过率 (GFR) 密切相关,影响其安全性和有效性.
- 评估狄戈辛对CHF患者功能的影响对于优化治疗至关重要.
研究的目的:
- 为了评估狄戈辛对心血管衰竭患者功能的影响.
- 为了确定狄戈辛是否会改变这一群体中关键的功能标志物.
- 为了研究消毒素使用与功能变化之间的潜在关联.
主要方法:
- 一项回顾性研究分析了30名CHF患者的数据,这些患者接受了狄戈辛治疗.
- 功能标志物 (eGFR,肌素,BUN) 和其他参数在狄戈辛治疗前后进行比较.
- 统计分析,包括t测试,用于评估功能指标的变化.
主要成果:
- 平均eGFR在迪戈辛治疗后显著下降 (p = 0.001).
- 迪戈辛显著增加了肝酶 (AST,ALT) 和肌酸酶.
- 没有观察到肌素,BUN,白蛋白或尿液水平的显著变化;血红蛋白显示显著下降.
结论:
- 在CHF患者中,迪戈辛可能会对功能产生不利影响,由降低的EGFR表明.
- 该研究的回顾性质和小样本大小限制了最终的结论.
- 建议进行更大规模的前性研究,以进一步调查在心血管衰竭中迪戈辛对脏的影响.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
598
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
598
01:22Heart Failure Drugs: Diuretics
400
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
400
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
01:30Heart Failure V: Medical Management
9
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
9
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
01:22Heart Failure Drugs: β-Blockers
346
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
346